AmbioPharm Nears Completion of Shanghai Building 2 Expansion 

FOR IMMEDIATE RELEASE 

North Augusta, SC, August  28, 2025– AmbioPharm, a leading global peptide contract development and manufacturing organization (CDMO), is putting the final touches on its Shanghai Building 2 expansion, with completion set for next month. 

The new facility will add nearly 75,000 square feet of commercial scale manufacturing space, featuring multiple 3,000L SPPS and LPPS lines, cleavage lines up to 2,000L and deprotection lines up to 1,000L. With these additions, AmbioPharm has scaled up GMP operations to enable batch sizes up to 50-100 kgs, supporting both conventional and fragment-based hybrid synthesis to meet the growing demand for peptide APIs.  

By expanding our capabilities, AmbioPharm continues to strengthen its ability to help customers meet critical timelines, scale efficiently, and ensure life-changing treatments reach patients without compromising quality.  

For more information about our capabilities and how we can support your next peptide project, please visit www.ambiopharm.com.  

About AmbioPharm  

AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.